Skip to main content

Precigen, Inc. (PGEN)

NASDAQ: PGEN · IEX Real-Time Price · USD
4.59 -0.08 (-1.71%)
Oct 22, 2021 4:00 PM EDT - Market closed
Market Cap948.49M
Revenue (ttm)101.01M
Net Income (ttm)-108.54M
Shares Out199.02M
EPS (ttm)-0.59
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume955,658
Open4.64
Previous Close4.67
Day's Range4.48 - 4.69
52-Week Range3.95 - 11.10
Beta2.36
AnalystsBuy
Price Target12.50 (+172.3%)
Est. Earnings DateNov 8, 2021

About PGEN

Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; proprietary methane bioconversion platform that turns natural gas into energy and chemical products; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic com...

IndustryBiotechnology
Founded1998
CEOHelen Sabzevari
Employees423
Stock ExchangeNASDAQ
Ticker SymbolPGEN
Full Company Profile

Financial Performance

In 2020, Precigen's revenue was $103.18 million, an increase of 13.73% compared to the previous year's $90.72 million. Losses were -$170.52 million, -47.10% less than in 2019.

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for Precigen stock is "Buy." The 12-month stock price forecast is 12.50, which is an increase of 172.33% from the latest price.

Price Target
$12.50
(172.33% upside)
Analyst Consensus: Buy

News

Precigen Appoints Harry Thomasian Jr. as Chief Financial Officer

GERMANTOWN, Md., Oct. 12, 2021 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of pa...

1 week ago - PRNewsWire

Implied Volatility Surging for Precigen (PGEN) Stock Options

Investors need to pay close attention to Precigen (PGEN) stock based on the movements in the options market lately.

2 weeks ago - Zacks Investment Research

Precigen Posts Additional Interim Data From Type 1 Diabetes Trial

Precigen Inc's (NASDAQ: PGEN) subsidiary Precigen ActoBio has announced additional interim data from Phase 1b/2a study of AG019 ActoBiotics for recent-onset type 1 diabetes (T1D). Related:   Precigen St...

3 weeks ago - Benzinga

Precigen ActoBio Announces Additional Positive Interim Data from Phase 1b/2a Study of AG019 ActoBiotics™, A Novel The...

GERMANTOWN, Md., Oct. 1, 2021 /PRNewswire/ -- Precigen ActoBio, an innovative clinical-stage biotechnology company focused on a new class of microbe-based therapeutic agents and a wholly-owned subsidiar...

3 weeks ago - PRNewsWire

Precigen to Present at the 2021 Wells Fargo Virtual Healthcare Conference and the H.C. Wainwright 23rd Annual Global ...

GERMANTOWN, Md., Sept. 1, 2021 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of pa...

1 month ago - PRNewsWire

Precigen, Inc. (PGEN) Reports Q2 Loss, Tops Revenue Estimates

Precigen, Inc. (PGEN) delivered earnings and revenue surprises of 16.67% and 49.38%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Precigen: Q2 Earnings Insights

Shares of Precigen (NASDAQ:PGEN) moved lower in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share were up 61.54% year over year to ($0.10), which beat the ...

2 months ago - Benzinga

Precigen Reports Second Quarter and First Half 2021 Financial Results

GERMANTOWN, Md., Aug. 9, 2021 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of pat...

2 months ago - PRNewsWire

Earnings Preview: Precigen, Inc. (PGEN) Q2 Earnings Expected to Decline

Precigen, Inc. (PGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

Precigen to Announce Second Quarter and First Half 2021 Financial Results on August 9th

GERMANTOWN, Md., Aug. 2, 2021 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of pat...

2 months ago - PRNewsWire

Precigen Stock Surges On Positive AG019 Data for Chronic Treatment Of Type 1 Diabetes

Precigen Inc's (NASDAQ: PGEN) subsidiary Precigen ActoBio announced topline results from the Phase 1b/2a study evaluating AG019 ActoBiotics to treat recent-onset type 1 diabetes (T1D). Results were pres...

4 months ago - Benzinga

Precigen ActoBio Announces Positive Topline Results from Phase 1b/2a Study of AG019 ActoBiotics™, A Novel Therapy Des...

GERMANTOWN, Md., June 10, 2021 /PRNewswire/ -- Precigen ActoBio, an innovative clinical-stage biotechnology company focused on a new class of microbe-based therapeutic agents and a wholly-owned subsidia...

4 months ago - PRNewsWire

Precigen to Present at the JMP Securities Life Sciences Conference

GERMANTOWN, Md,, June 10, 2021 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of pa...

4 months ago - PRNewsWire

Precigen, Inc. (PGEN) Reports Q1 Loss, Tops Revenue Estimates

Precigen, Inc. (PGEN) delivered earnings and revenue surprises of 31.25% and 23.51%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

Precigen Reports First Quarter 2021 Financial Results

GERMANTOWN, Md., May 10, 2021 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of pat...

5 months ago - PRNewsWire

Precigen, Inc. (PGEN) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Precigen, Inc. (PGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

5 months ago - Zacks Investment Research

Exclusive: Precigen's CEO Breaks Down Biotech's Oncology Platforms, Technology, Differentiators

Cancer treatment has evolved from the use of chemotherapeutic anti-tumor drugs to targeted therapies to monoclonal antibodies to immunotherapies to new, personalized therapeutics. Precigen, Inc. (NASDAQ...

6 months ago - Benzinga

Precigen Announces Departure of Chief Financial Officer

GERMANTOWN, Md., March 30, 2021 /PRNewswire/ -- Precigen, Inc., a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today ...

6 months ago - PRNewsWire

Precigen Announces First Patient Dosed for PRGN-2012 AdenoVerse™ Immunotherapy in Patients with Recurrent Respiratory...

GERMANTOWN, Md., March 23, 2021 /PRNewswire/ -- Precigen, Inc., a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today ...

7 months ago - PRNewsWire

Precigen Receives FDA Orphan Drug Designation for PRGN-2012 AdenoVerse™ Immunotherapy in Patients with Recurrent Resp...

GERMANTOWN, Md., March 18, 2021 /PRNewswire/ -- Precigen, Inc., a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today ...

7 months ago - PRNewsWire

Precigen, Inc. (PGEN) Reports Q4 Loss, Lags Revenue Estimates

Precigen, Inc. (PGEN) delivered earnings and revenue surprises of 31.25% and -16.13%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

7 months ago - Zacks Investment Research

Precigen Reports Fourth Quarter and Full Year 2020 Financial Results

GERMANTOWN, Md., March 1, 2021 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of pa...

7 months ago - PRNewsWire

Will Precigen, Inc. (PGEN) Report Negative Q4 Earnings? What You Should Know

Precigen, Inc. (PGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

8 months ago - Zacks Investment Research

3 Troll-able Stocks That Could Be the Next GME

The next GME will be hard to find, but these three stocks could be solid candidates for a potential short squeeze. The post 3 Troll-able Stocks That Could Be the Next GME appeared first on InvestorPlace.

Other symbols:CLVSNAKD
8 months ago - InvestorPlace

Precigen to Participate in Guggenheim Healthcare Talks Oncology Day

GERMANTOWN, Md., Feb. 4, 2021 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of pat...

8 months ago - PRNewsWire